YERVOY®
(ipilimumab)

Patient
Alert Card

Bristol-Myers Squibb

20161019 Yervoy Global PAC October2016 artwork v1_35.indd 121/10/2016 17.43.44



YERVOY® (ipilimumab)

This card has important information.

Always carry this card with you and show it to any doctor you may need to see (on holiday for example).

IMPORTANT INFORMATION

Tell your Doctor right away if you have any of these symptoms

BOWEL AND STOMACH[1]

- diarrhoea (watery, loose or soft stools), bloody or darker-coloured stools
- more frequent bowel movements than usual
- pain or tenderness in your stomach or abdominal area, nausea, vomiting

LIVER1

- eye or skin yellowing (jaundice)
- pain on the right side of your stomach area
- tiredness
- dark urine

SKIN1

- skin rash with or without itching
- blisters and/or peeling of the skin, mouth sores
- dry skin

GENERAL1

- fever, headaches, tiredness
- bleeding
- behavioural changes (e.g. less sex drive, being irritable or forgetful)

NERVE1

- muscle weakness
- numbness or tingling in legs, arms, or face
- dizziness, loss of consciousness or difficulty waking up

EYE[1]

- redness in the eye
- pain in the eye
- vision problems or blurry vision

- Report any of these symptoms to your doctor right away
- Symptoms that may appear mild can quickly worsen if left untreated[1]
- Early treatment of side effects reduces the likelihood that ipilimumab treatment will need to be temporarily or permanently stopped, allowing you to get the maximum benefit from treatment.
- Signs and symptoms may be delayed and may occur weeks to months after your last injection[1]
- Don’t try to treat these symptoms yourself without consulting with your doctor first
- Carry this Patient Alert Card and show to any doctor you might interact with, and say that you are being treated with ipilimumab.

You can get more information on YERVOY® Package Leaflet

My physician's contact information

Name of Physician

Office Phone

After-hours Phone

My Name and Phone

Name of Caregiver (in case of emergency)

IMPORTANT information for healthcare providers

- This patient is treated with YERVOY®, a drug used for the treatment of melanoma.
- Immune-related Adverse Reactions (irARs), can mostly occur during the induction period, but may appear months after the last dose of YERVOY®.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications. YERVOY® specific management guidelines for irARs are available.[2]
- If you are a doctor not specialized in oncology, please contact a melanoma specialist.

Any suspected adverse events should be reported to Medicines Authority. ADR report forms can be downloaded from www.medicinesauthority.gov.mt/adrportal and sent to postlicensing.medicinesauthority@gov.mt or sent to Medicines Authority, Sir Temi Zammit Buildings, Malta Life Sciences Park, San Gwann SGN 3000, Malta.

Please consult YERVOY® Summary of Product Characteristics at www.ema.europa.eu or call Medical Information at 00356 23976505 for more information.

1. YERVOY™ Package Leaflet
2. YERVOY™ Summary of Product Characteristics

731MT16NP07531-01 Approval date: 08-Nov-2016